[On the pharmacotherapeutic treatment of cerebral palsy. II. Treatment of oligophrenia and epilepsy].
D002547:Cerebral Palsy / Q000150:complications*; D002648:Child; D002675:Child, Preschool; D002746:Chlorpromazine / Q000627:therapeutic use*; D004827:Epilepsy / Q000188:drug therapy*; D004832:Epilepsy, Absence / Q000188:drug therapy*; D005971:Glutamates / Q000627:therapeutic use*; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D008607:Intellectual Disability / Q000188:drug therapy*; D009132:Muscles / Q000627:therapeutic use*; D010880:Piperidines / Q000627:therapeutic use*; D011736:Pyridoxine / Q000627:therapeutic use*; D012313:RNA / Q000627:therapeutic use*; D012110:Reserpine / Q000627:therapeutic use*; D013036:Spasms, Infantile / Q000188:drug therapy*
D005971:Glutamates; D010880:Piperidines; D012313:RNA; D012110:Reserpine; D011736:Pyridoxine; D002746:Chlorpromazine
Uber die pharmakotherapeutische Behandlung der cerebralen Kinderlähmung. II. Behandlung der sich an die Krankheit anschliessenden Oligophrenie und Epilepsie.